Table 3.
Association of rs45446698 genotype with ER + /PR + breast cancer risk among women of European ancestry stratified by current use of postmenopausal hormone treatment.
| iCOGS | OncoArray | Combined | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Controls | OR (95% CI) | P1 | Cases | Controls | OR (95% CI) | P1 | Cases | Controls | OR (95% CI) | P1 | |
| MHT− | 3742 | 8902 | 0.73 (0.62–0.86) | 0.0002 | 5961 | 15,128 | 0.95 (0.83–1.08) | 0.45 | 9703 | 24,030 | 0.86 (0.78–0.95) | 0.003 |
| MHT + | 1593 | 2859 | 0.77 (0.59–0.99) | 0.04 | 2823 | 5529 | 0.87 (0.71–1.06) | 0.16 | 4416 | 8388 | 0.83 (0.70–0.97) | 0.02 |
| NK | 622 | 1793 | 3090 | 6226 | 3712 | 8019 | ||||||
| Total | 5957 | 13,554 | Pint = 0.81 | 11,874 | 26,883 | Pint = 0.26 | 17,831 | 40,437 | Pint = 0.47 | |||
| EPT− | 3736 | 7826 | 0.77 (0.65–0.91) | 0.002 | 4173 | 8566 | 0.93 (0.80–1.09) | 0.38 | 7909 | 16,392 | 0.85 (0.76–0.95) | 0.005 |
| EPT + | 727 | 944 | 0.71 (0.48–1.05) | 0.09 | 878 | 1170 | 0.66 (0.45–0.97) | 0.03 | 1605 | 2114 | 0.68 (0.52–0.90) | 0.007 |
| NK | 1494 | 4784 | 6823 | 17,147 | 8317 | 21,931 | ||||||
| Total | 5957 | 13,554 | Pint = 0.72 | 11,874 | 26,883 | Pint = 0.09 | 17,831 | 40,437 | Pint = 0.15 | |||
| ET− | 3840 | 7710 | 0.75 (0.63–0.88) | 0.0005 | 4343 | 8136 | 0.92 (0.79–1.07) | 0.29 | 8183 | 15,846 | 0.88 (0.79–0.97) | 0.01 |
| ET + | 589 | 1172 | 0.69 (0.45–1.06) | 0.09 | 640 | 1484 | 0.94 (0.62–1.42) | 0.76 | 1229 | 2656 | 0.84 (0.64–1.10) | 0.21 |
| NK | 1528 | 4672 | 6891 | 17,263 | 8419 | 21,935 | ||||||
| Total | 5957 | 13,554 | Pint = 0.83 | 11,874 | 26,883 | Pint = 0.85 | 17,831 | 40,437 | Pint = 0.78 | |||
MHT menopausal hormone treatment, EPT oestrogen–progesterone therapy, ET oestrogen-only therapy, P1 test of H0 no association between rs45446698 and ER + /PR + breast cancer risk, Pint test of H0 no difference between stratum-specific estimates, NK not known.
Studies with less than 50 cases in any stratum were excluded from the stratified analyses leaving 13 studies for analysis in iCOGS data and 27 studies for analysis in OncoArray data. All models are adjusted for reference age, study, ten principal components and former use of MHT. Additionally, when stratified by EPT or ET, models are adjusted for use of any other type of MHT other than the one of interest. Further adjusting for age at menarche (<12, 12, 13, 14, >14), parity (0, 1, 2 and ≥3 live births) and BMI ( < 18.5, 18.5–<20.0, 20.0–<25.0, 25.0–<30.0 and ≥30.0 kg/m2) did not alter these results.